Biotech Reporter PDF Download

Author:
Publisher:
ISBN:
Category : Agricultural biotechnology
Languages : en
Pages : 1120

View

Book Description

Author: Peter Loftus
Publisher: Harvard Business Press
ISBN: 164782320X
Category : Business & Economics
Languages : en
Pages : 299

View

Book Description
The inside story of an unprecedented feat of science and business. At the start of 2020, Moderna was a biotech unicorn with dim prospects. Yes, there was the promise of its disruptive innovation that could transform medicine by using something called messenger RNA, one of the body's building blocks of life, to combat disease. But its stock was under water. There were reports of a toxic work culture. And despite ten years of work, the company was still years away from delivering its first product. Investors were getting antsy, or worse, skeptical. Then the pandemic hit, and Moderna, at first reluctantly, became a central player in a global drama—a David to Big Pharma's Goliaths—turning its technology toward breaking the global grip of the terrible disease. By year's end, with the virus raging, Moderna delivered one of the world's first Covid-19 vaccines, with a stunningly high rate of protection. The achievement gave the world a way out of a crippling pandemic while validating Moderna's technology, transforming the company into a global industry power. Biotech, and the venture capital community that fuels it, will never be the same. Wall Street Journal reporter Peter Loftus, veteran reporter covering the pharmaceutical and biotech industries and part of a Pulitzer Prize–finalist team, brings the inside story of Moderna, from its humble start at a casual lunch through its heady startup days, into the heart of the pandemic and beyond. With deep access to all of the major players, Loftus weaves a tale of science and business that brings to life Moderna's monumental feat of creating a vaccine that beat back a deadly virus and changed the business of medicine forever. The Messenger spans a decade and is full of heroic efforts by ordinary people, lucky breaks, and life-and-death decisions. It's the story of a revolutionary idea, the evolution of a cutting-edge American industry, and one of the great achievements of this century.

Author: Tom Abate
Publisher: Times Books
ISBN: 146685121X
Category : Business & Economics
Languages : en
Pages : 308

View

Book Description
A sophisticated investor's practical tool kit for analyzing the science, business, opportunities, and risks in the century's most promising industry The world is entering a biotechnology boom-but only informed investors will prosper in the incredibly complex biotech business. Separating the bioengineered wheat from the chaff, San Francisco Chronicle science and technology columnist Tom Abate, one of the top objective authorities on biotech, gives investors the analytical foundation to understand the science, finances, time horizon, and technological and commercial potential of this burgeoning industry. In The Biotech Investor, Abate provides sophisticated business analysis, guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He explains how breaking news, medical conferences, U.S. Food and Drug Administration approvals, and the patent process affect investing strategies. Finally, he looks beyond medicine to review the financial opportunities presented by biotechnology advances in everything from agriculture to jean manufacturing, and shows investors how to identify "coattail" industries such as instrumentation and software development that will benefit from biotech successes. The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries.

Author: Moira Anne Gunn
Publisher: Amacom Books
ISBN: 9780814409237
Category : Biography & Autobiography
Languages : en
Pages : 286

View

Book Description
Funny, entertaining, and informative, the host of public radios "Tech Nation" gives readers a unique, inside look at biotechnology today and a glimpse at what could be in store for tomorrow.

Author: Marcus Wohlsen
Publisher: Penguin
ISBN: 9781617230028
Category : Science
Languages : en
Pages : 240

View

Book Description
A tour of the latest breakthroughs in do-it-yourself DNA science makes optimistic predictions for the near future, citing the achievements of leading underground contributors while revealing the potential of specific endeavors. 25,000 first printing.

Author: Dan Charles
Publisher: Basic Books
ISBN: 0786723769
Category : History
Languages : en
Pages : 390

View

Book Description
Once confined to the research laboratory, the genetic engineering of plants is now a big business that is changing the face of modern agriculture. Giant corporations are creating designer crops with strange powers-from cholesterol-reducing soybeans to plants that act as miniature drug factories, churning out everything from vaccines to insulin. They promise great benefits: better health for consumers, more productive agriculture-even an end to world hunger. But the vision has a dark side, one of profit-driven tampering with life and the possible destruction of entire ecosystems. In Lords of the Harvest, Daniel Charles takes us deep inside research labs, farm sheds, and corporate boardrooms to reveal the hidden story behind this agricultural revolution. He tells how a handful of scientists at Monsanto drove biotechnology from the lab into the field, and how the company's opponents are fighting back with every tool available to them, including the cynical manipulation of public fears. A dramatic account of boundless ambition, political intrigue, and the quest for knowledge, Lords of the Harvest is ultimately a story of idealism and of conflicting dreams about the shape of a better world.

Author:
Publisher:
ISBN:
Category : Agricultural biotechnology
Languages : en
Pages : 794

View

Book Description

Author: Paul Huybrechts
Publisher: Désiré Collen
ISBN: 164999608X
Category : Biography & Autobiography
Languages : en
Pages : 290

View

Book Description
Désiré Collen, Biotech Pioneer relates the fascinating story of scientific discovery in a time when biotechnology was not yet a science. Although the cultivation and cross fertilization of plants were, strictly speaking, biotechnological techniques, modern biotechnology dates from the early 1970s, when pioneers such as biochemist Herbert Boyer from the university of California managed to transfer genetic material into a bacterium. Together with venture capitalist Robert Swanson, Boyer set up Genentech, one of the first genetic engineering companies. Just a few years later, on the other side of the Atlantic, in Leuven, Désiré Collen discovered t-PA, the enzyme responsible for fibrinolysis, or the dissolving of blood clots. Clogged arteries were then still one of the major causes of death. The ensuing cooperation between Collen and Genentech was the beginning of a long-lasting success story, from which not only Collen but also scientific research and the University of Leuven benefitted greatly for many years. According to a Reuters ranking, KU Leuven has been, from 2016 onwards, the most innovative university in Europe. Flanders and Belgium served as the cradle of several highly successful biotech companies. t-PA was a relatively expensive medicine, and Collen went on to develop a much cheaper clot-dissolving remedy to benefit patients in less affluent countries. He failed, however, to find the necessary finances for Phase 3 trials. Meanwhile, he had set up ThromboGenics, a company which later specialized in ophthalmology. Collen continued to stimulate and finance research in other fields, such as the cardiovascular research of Peter Carmeliet. In 2013 he left ThromboGenics, following a difference in views on the company’s focus, and in 2015 he set up Fund+, a biotech-oriented investment firm. Fund+ has meanwhile acquired a prominent place among European biotech investment funds and has scored some astonishing early successes. In June 2020, Fund+ had 13 companies in its portfolio, with several more waiting to come on board.

Author: Sally Smith Hughes
Publisher: University of Chicago Press
ISBN: 0226359204
Category : Business & Economics
Languages : en
Pages : 231

View

Book Description
In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech’s improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech’s science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech’s founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, Genentech tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.

Author: Jim Mellon
Publisher: John Wiley & Sons
ISBN: 1119963184
Category : Business & Economics
Languages : en
Pages : 363

View

Book Description
Everything you need to know about the most important trend in the history of the world Within most people's lifetimes, the developments in the biotechnology sector will allow us to live increasingly long and healthy lives, as well as provide us with technological innovations that will transform the way we live. But these innovations offer more than just hope for a better life, but hope for better returns too. Financial returns of incredible magnitude await savvy investors and businesspeople who can see the massive changes on the horizon. This book details these fast-moving trends and innovations and offers extensive advice on how to profit from them in business and investing.